Aggressive Lung Adenocarcinoma Subtype May Require New Treatment Strategy

By Jim Stallard,

Thursday, September 17, 2015

Microscopic image of lung cancer cells

Doctors are now able to identify whether patients with early-stage lung adenocarcinoma have an aggressive form called solid predominant subtype. Following surgery, this type of lung adenocarcinoma often returns within two years in multiple locations, even when tumors are small. These patients may require closer follow-up and adjuvant treatments in addition to surgery in order to reduce risk of recurrence.

  • Patients with early-stage lung adenocarcinoma traditionally had surgery alone.
  • An aggressive subtype often returns after surgery even when tumors are small.
  • Surgeons and oncologists are now able to identify this subtype.
  • This form of lung adenocarcinoma is called solid predominant subtype.
  • These patients may require closer follow-up and additional treatments.

Patients with early-stage lung adenocarcinoma, the most common form of lung cancer in the United States, typically have their tumors surgically removed without additional treatment. This has been the standard therapy for stage I patients whose tumors are small and have not spread to nearby lymph nodes.

Now research led by Memorial Sloan Kettering thoracic surgeon and scientist Prasad Adusumilli has identified a subset of these patients whose cancer is more likely to return soon after removal, often appearing in multiple locations and ultimately proving more lethal.

These patients have a form of lung adenocarcinoma called solid predominant subtype.

“Our study shows that tumor size alone is not sufficient in predicting how the cancer will behave,” says Dr. Adusumilli. “We can now identify aggressive tumors among early-stage lung cancers, and these patients may require closer follow-up and additional adjuvant treatments, such as chemotherapy, or newer therapies which include drugs that target specific genetic mutations.”

We can now identify aggressive tumors among early-stage lung cancers.
Prasad S. Adusumilli
Prasad S. Adusumilli thoracic surgeon

Until now, surgery was thought to be sufficient for treating patients with tumors less than 5 centimeters in diameter. The new study, published in the Journal of Clinical Oncology, shows that some of these tiny tumors — even those smaller than 2 centimeters — come roaring back soon afterward.

This finding could change the course of treatment for a significant number of patients with lung adenocarcinoma, a form of non-small cell lung cancer. Although currently only about 20 percent of patients are diagnosed before the cancer has spread to other parts of the body, this portion is expected to increase as more people undergo low-dose CT scans to screen for the disease. Medicare recently approved coverage of these scans for people who are at high risk for lung cancer due to smoking.

Stark Differences among Subtypes

There has been a growing appreciation that the multiple subtypes of lung adenocarcinoma behave differently. As a result of tumor data from MSK and other cancer centers, the International Association for the Study of Lung Cancer (IASLC), the American Thoracic Society (ATS), and the European Respiratory Society (ERS) jointly issued a new tumor classification system in 2011 that characterizes lung adenocarcinomas as a mixture of five subtypes based on histology (how cancer cells look under a microscope).

To help determine prognosis, pathologists now report the proportions of the five subtypes within the tumor — including the predominant subtype, which makes up the highest proportion of tumor tissue — as well as tumor size.

CT scan of lung cancer

The new classification system has already begun to change the management of lung adenocarcinomas. In 2013, Dr. Adusumilli, working with MSK pathologist William Travis, showed that a subtype called micropapillary (MIP) morphology was more likely to recur after a limited operation known as wedge resection, in which the tumor and only a small amount of surrounding tissue are removed. This high rate of recurrence held true even for MIP tumors smaller than 2 centimeters.

However, the recurrence rate was lower if the patient had undergone a more extensive procedure called lobectomy, which removes the tumor along with up to a third of the lung. This discovery has helped guide doctors in deciding how much of the lung must be removed to adequately reduce risk of MIP recurrence.

Back to top

Rapid Recurrence at Multiple Sites

In the new study, Dr. Adusumilli and colleagues investigated how various subtypes were related to recurrence in a larger group of patients. They looked at more than 1,000 stage I lung adenocarcinoma patients who had their tumors removed at MSK and who were followed afterward with CT scans for an average of five years. They found that the solid predominant subtype, which made up one in seven stage I tumors, was especially aggressive.

Patients with this subtype had a 33 percent risk of recurrence over five years, compared with a risk of only 17 percent in the entire group. More importantly, solid predominant tumors usually recurred within two years, often at locations outside the chest area. The chance of recurrence was actually highest at the one-year mark. Patients with the solid predominant subtype were also more likely to die from their lung cancer more quickly after the cancer returned.

Solid predominant tumors usually recurred within two years, often at locations outside the chest area.

“With the risk of recurrence peaking at one year and the cancer coming back outside the chest at multiple sites, it shows this is a very aggressive subtype that has either already spread undetected or spreads quickly and has poor outcomes,” Dr. Adusumilli says. “If I operate on a patient now and see a solid predominant tumor, I know the chance of it coming back is high, so I need to closely follow up with more frequent CT scans and possibly add adjuvant therapy to help decrease that risk.”

Back to top

Identifying Aggressive Tumors before Surgery

Dr. Adusumilli emphasizes the urgent need to identify these aggressive tumors well before operating. His laboratory, along with others at MSK, is already working on identifying several markers that can serve as early detection indicators.

He also underscores the importance of surgeons working closely with pathologists to determine tumor subtype and choose the best course of treatment for the patient after the tumor is removed. “Even for these early-stage tumors, we need the kind of multidisciplinary approach that is possible at centers like ours that involves the highly developed expertise of our pathologists to help surgeons make the best treatment decisions,” he says. 

Back to top

This research was supported by Grant No. LC110202 from the US Department of Defense. 


My very dear friend was diagnosed with Adenocarcinoma in 7areas including his back that he had to have surgery or chance not walking again ! I'm not understanding all of this. Can you please help me understand ?

We're sorry to hear about your friend's diagnosis. Adenocarcinoma can originate in many different organs in the body, and then can spread to other locations. Without more detail about where your friend's tumor originated, we are not able to provide information on how this cancer might be treated. We recommend you call the National Cancer Institute's Cancer Information Service at 800-4CANCER if you'd like to discuss this with someone. Thank you for your comment.

My husband was diagnosed this week with NSCAC that has spread to the adrenal gland. After CT, MRI and X-ray of everything from his brain to his pelvis, they find no tumor. Left adrenal glad is 4X normal size. Lots of cells in the pleural lining of the lung and a CEA of 16. How common is adenocarcenoma without a mass?

Currently a pat. of Dr.M.D.Hellmann, MD I was a pat. of Dr. Seagals and MEDI 4736 clinical trial. NSC stage 4 in right lung, limp nod, and brain. It's gone It's all good Thank God and the DR. at you Hospital.

On Nov 4, 2015 , had my upper right lobe resected due to Adenoma Carcinoma. Lymph nodes all clear, cancer gone per Pathology report. How do I get the sub type identified moving forward? Is sub type identity mandatory to plan for future scans or recurrence?b Should the pathology report include sub typing of one of five sub types of Adenoma Carcinoma? 69 year old female pleased with robotic resection and post op so far. Patient of Kathryn O'Keefe, MD. Cincinnat, OH

Ann, thank you for your question. We recommend you speak with your doctor about the pathology report and finding out what subtype you have. If you are interesting in making an appointment with a Memorial Sloan Kettering physician for a consultation, please call our Physician Referral Service at
800-525-2225 or go to­care/appointment.

eXcellent site and I am now able to understand my recent Lobectomy for Adenoma Carcinoma. Now, wondering what my sub type is. Your site has enabled me to have the right inquiries & followup questions Thank you,


Viola, we are unable to comment or speculate on individual cases. We are very sorry for the loss of your mother.

What happens once the fluid is removed and it is not accumulating anymore. I am sure they take the drainage out, but what is next. My mother is thinking she is going to be cured but after going through my own cancer I do not believe that is the case. I am heartbroken as she seems not to have a clue that this is fatal, even though her doctor at Mt Sinai told her. I am a little confused as well why she wasn,t able to get surgery. I just read above that radiation does not affect the cancer. Please tell me what to expect and also are there any questions I should ask her doctor. I will be meeting for the first time in 2 weeks as I live distant to my mom. THanks in advance.

Seth, thank you for reaching out. We suggest you speak with your mother's physicians about these questions as we are unable to provide specific medical advice--every patient's individual case is affected by a large number of factors. At Memorial Sloan Kettering, we provide emotional support and strength to deal with cancer, and we suggest you consult with her physician to find out about similar support (patient support, including counseling) that provide these benefits.

I had a lobectomy of the right upper lung on Jan 11, 2016. Am still in the hospital & found you site extremely helpful in understanding all this. Before my surgery, I thought it would be a "walk in the park". The tumor was thought to be small, they would cut it out & happy days again. I was totally unprepared for the roller coaster that lied ahead. I had a PET scan before surgery & no other cancer was found. Now I was told it is adenocarcinoma and my type could have spread to the brain, a CT is ordered but then the agony of waiting for results. I hope we can talk about the Lord on this site because I prayed all night. It was all negative. Then we are told Chemo may be necessary to make sure it does not spread. After another day we find out the 5 year follow plan will be sufficient as it was stage 1B. I didn't mean to get so lengthly with this but was unprepared to know what questions to ask. My medical team is top notch but I suspect they thought I on top of it all when I had no questions to ask. Your sight has really explained the things I needed to know & I hope my comment helps someone who has just learned they have cancer. Thank you & Bless your Cancer Center and this site.

Edwina, we're very happy that our site has been helpful to you. Best wishes for you in your recovery, and thank you for your kind words.

I was diagnosed yesterday with pulmonary adenocarcinoma (bronchoscopy biopsy). The pathology report as follows :
> malignant cells are strongly positive for TTF1 while negative for p63.
> histologic features support poorly differentiated histology and a spindled component.
I currently have two tumors both under 2 centimeters.
What does the report really tell me ??

Dear Larry, we are sorry to hear about your diagnosis. It's best to talk to your doctor to interpret the results of your pathology report and how it will impact your treatment options and prognosis.

You may also be interested in checking out the American Society of Clinical Oncology (ASCO)'s website for patients, which offers some great patient education resources, including information about how to read your pathology report:….

We hope this is helpful. Thank you for reaching out to us.

I have a 59yo patient diagnosed with primary adenoca lung Grade 4. He would like to come to SK Centre for assessment & treatment. Pls advise who the most appropriate specialist would be.
We reside in Sydney, Asutralia.

Dear Dr. Bakaric, our International Center can assist you in making arrangements for either a medical records review by mail or in making an appointment for your patient with the most appropriate specialist. Please contact them directly at or for more information go to Thank you for reaching out to us.

Add new comment

We welcome your questions and comments. While we share many of them with our world-class doctors and researchers, we regret that in order to protect your privacy, we are not able to make personal medical recommendations on this forum, nor do we publish comments that contain your personal information. If you would like to consult with an MSK doctor, we encourage you to make an appointment at 800-525-2225 or request an appointment online.

Your email address is kept private and will not be shown publicly.